GSK secures ex-Greater China rights to KRAS-EGFR therapy; $110M upfront
GSK won global licensing rights excluding Greater China to develop and commercialize a KRAS-EGFR antibody-targeted cancer therapy. Deal includes $110 million upfront plus up to $1.185 billion in milestones, with initial trials starting in H2 2026.
A global licensing deal gives GSK rights, excluding Greater China, to develop and commercialize a novel KRAS-EGFR antibody-targeted therapy for major cancers. The agreement includes $110 million upfront and up to $1.185 billion in milestones. Initial trials are set to begin in H2 2026.